Latest Temozolomide Stories
WASHINGTON, March 17, 2011 /PRNewswire/ -- Novocure announced today that the U.S.
New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.
The deletion of a gene called NFKBIA may cause glioblastoma, the most common and malignant brain cancer.
A study fast-tracked for online publication Dec. 22 in the New England Journal of Medicine has identified an important gene deletion in up to one of every four cases of glioblastoma, the most common adult brain cancer.
SEATTLE, Nov. 22, 2010 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.
A new vaccine added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma (GBM), the most deadly form of brain cancer.
CHICAGO, June 5 /PRNewswire/ -- Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
MISSISSAUGA, May 21 /PRNewswire-FirstCall/ - YM BioSciences Inc.
- The word or words serving to define another word or expression, as in a dictionary entry.